Tirzepatide
Also known as: Mounjaro, Zepbound
A dual incretin agonist targeting both GIP and GLP-1 receptors. Shows superior weight loss and glycemic control compared to GLP-1-only agonists.
Mechanism of Action
Dual agonism of GIP and GLP-1 receptors enhances insulin sensitivity, reduces appetite, and improves metabolic function through complementary pathways.
Dosing Protocol
Start 2.5mg/week for 4 weeks, titrate to 5mg, then 7.5mg, 10mg, 12.5mg, up to 15mg/week.
Open peptide calculatorReconstitution
Research-grade: 5mg vial + 2mL BAC water.
Storage
Refrigerate 2-8°C. Do not freeze.
Side Effects
- ●Nausea
- ●Diarrhea
- ●Decreased appetite
- ●Injection site reactions
Key Research Findings
- ●SURMOUNT-1: up to 22.5% weight reduction
- ●Superior to semaglutide in head-to-head trials
- ●Improved insulin sensitivity beyond weight loss alone
Latest Verified Lab Report
No lab reports available for Tirzepatide yet.
Community-funded testing results will appear here.
Vendor Trust Leaderboard
Trust leaderboard coming soon.
Vendor rankings based on verified lab test results.
Active Deals
15% off with code at checkout.
10% off with code at checkout.
10% off — discount applied automatically via referral link.
10% off with code at checkout.
Sponsored Ad Space
Advertise with usResearch Use Only
This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.